ABBV vs HON: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Honeywell International Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-26.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
Honeywell International Inc. · Industrials
$212.55
-8.5% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
ABBV has more upside to fair value
(-1.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
HON |
| Current Price |
$261.70 |
$212.55 |
| Fair Value Estimate |
$259.04 |
$194.50 |
| Upside to Fair Value |
-1.0%
|
-8.5%
|
| Market Cap |
$462.4B |
$67.4B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
7.4x
|
| Price / Sales |
7.2x
|
1.9x
|
| Price / FCF |
23.6x
|
16.4x
|
| Revenue Growth YoY |
+10.2%
|
-6.1%
|
| Gross Margin |
71.5%
|
36.6%
|
| Operating Margin |
29.3%
|
14.1%
|
| Return on Equity |
-136.5%
|
41.7%
|
| Dividend Yield |
2.61% |
2.09% |
| FCF Yield |
4.25%
|
6.11%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Honeywell International Inc. is a 101,000-employee diversified industrial technology and manufacturing conglomerate, led by CEO Vimal Kapur, spanning Aerospace, Building Technologies, Performance Materials and Technologies, and Safety and Productivity Solutions. Business quality is solid but not exceptional: the company carries a durable intangible-asset and switching-cost moat in aerospace avion…
Accumulation Zones
| Metric |
ABBV |
HON |
| Zone Low |
$194.28 |
$145.88 |
| Zone High |
$220.18 |
$165.32 |
| In Buy Zone? |
No
|
No
|